Caixin
Caixin Global – Latest China News & Headlines

Home >

TRENDING
Pony AI, WeRide Seek to Raise Combined $1.3 Billion in Hong Kong
MiniMax Unveils M2 Model to Compete on Speed and Cost
Tech Brief (Oct. 27): Huawei EV Partner Seres Unveils Hong Kong IPO Plan
LATEST
Huawei’s Bold AI Bet Aims to Fill Nvidia’s Void in China
China’s STAR Market Embraces Unprofitable Tech With $14.6 Billion ESWIN Debut
China Mobile Names China Unicom Chief as New Chairman
MiniMax Unveils M2 Model to Compete on Speed and Cost
Pony AI, WeRide Seek to Raise Combined $1.3 Billion in Hong Kong
Tech Brief (Oct. 28): Meituan Releases Open-Source Video Generation Model
Tech Brief (Oct. 27): Huawei EV Partner Seres Unveils Hong Kong IPO Plan
Tech Brief (Oct. 24): China Vows to Accelerate Tech Self-Reliance
Tech Brief (Oct. 23): China Cracks Down on Smart Devices Over Data Violations
Chinese Firms Urged to Fortify Online Brands as Cybersquatting Costs Mount
Tech Brief (Oct. 16): China’s Tech Minister Meets With Apple CEO
China Debuts Ultrafast Oscilloscope in Drive to Break Tech Barriers
Tech Brief (Oct. 15): Google to Invest $15 Billion in India for AI Hub
Tech Brief (Oct. 13): Wingtech Temporarily Loses Control of Dutch Chipmaker Nexperia
Tech Brief (Oct. 10): China’s AI Server Market Doubles
Tech Brief (Oct. 9): SoftBank to Acquire ABB’s Robotics Business
Tech Brief (Sept. 30): U.S. Widens Export Blacklist
U.S. Tightens Export Controls to Cover Subsidiaries of Blacklisted Firms
DeepSeek Unveils New Model With Sparse Attention, Slashes API Costs
Tech Brief (Sept. 29): Meituan’s Food-Delivery Platform Keeta Launches in Dubai

By Han Wei / Dec 27, 2018 06:47 AM / Business & Tech

Photo: VCG

Photo: VCG

A Chinese herbal drugmaker is under public scrutiny after an online article went viral accusing the company of misleading advertising of a cancer treatment that was linked to the death of a 4-year-old girl in 2015.

Tianjin-based Quanjian Nature Medicine Technology Development Co. Ltd. faced a public outcry after Dingxiangyuan, an online health information service, published an article Dec. 25 accusing the company of using false advertising to cheat consumers.

The article linked Quanjian to the death of a girl who suffered from cancer and missed the opportunity of cure by taking therapy provided by Quanjian. The drugmaker denied any wrongdoing and demanded an apology from Dingxiangyuan, which refused.

Quanjian described itself as China’s biggest direct seller of herbal-based medicine and health-care products. Public records showed that the company’s 2017 revenue totaled more than 1 billion yuan ($145 million) with net profit of 128 million yuan.

A Caixin search of health-care product registration records found that only 13 among more than 100 products sold by Quanjian have proper registration records. Quanjian declined to comment.

The controversy surrounding Quanjian prompted the state market regulator to issue a notice Wednesday tightening requirements on marketing activities of direct sellers of health-care products.

A previous version of this story misstated the company’s name as Quanjian Group. It is Quanjian Nature Medicine Technology Development Co. Ltd., the major unit of Quanjian Group.

Share this article
Open WeChat and scan the QR code